It is the epilogue of a soap opera that agitated the political class in the fall of 2024. Sanofi announced, Wednesday, April 30, the finalization of the sale of 50 % of Opella’s shares, parent company in Doliprane, the best -selling drug in France. It is now the American investment fund CD & R, which will preside the destinies of the ex-Filiale of Sanofi.
Eager to concentrate his efforts on his portfolio of innovative treatments and vaccines, Sanofi had expressed his intention, in September 2023, to separate from his subsidiary of prescription drugs and food supplements.
A year later, on October 21, 2024, the Tricolore group announced that it had initiated exclusive negotiations with the American CD&R, in order to give it half of the capital of its consumer health division. The completed transaction, Sanofi, which specifies having “Received a total net amount in cash in the order of 10 billion euros”therefore retains 48.2 % of Opella’s shares.
Health sovereignty
The Bpifrance public bank will hold the remaining 1.8 % of the capital of the company and obtains a headquarters on the board of directors. The government had negotiated this acquisition after the bronca aroused in the fall by the announcement of the transfer. Elected officials of all stripes were then brought up against sale, worried about possible consequences on employment and health sovereignty of this passage under foreign pavilion.
You have 34.12% of this article to read. The rest is reserved for subscribers.